C&EN Whitepaper
Powering Pharma with Artificial Intelligence

Brought to you by MilliporeSigma

Artificial intelligence (AI) has the potential to reinvent the pharmaceutical industry, where drug development tends be costly and time-consuming. Companies are looking for opportunities to employ new AI techniques to improve the quality and exchange of data, to automate processes, and to integrate instruments. The tools to make these changes happen are beginning to roll out. Digitizing data is a critical first step, allowing pharmaceutical companies to capitalize on the AI technology that is poised to deliver the next generation of medicines.

Key Objectives:
  • At least 17 AI-based companies have announced drug discovery partnerships with big biotechnology or pharmaceutical companies over the last decade.
  • AI applications in the pharmaceutical industry include predicting molecular interactions, accelerating clinical trials, sifting through libraries of compounds, and automating data collection.
  • To get the most out of AI technology, data storage, preparation, and sharing needs to evolve.

Brought to you by:
Please complete the form to download the whitepaper.
*MilliporeSigma, the vibrant M, and Synthia are trademarks of Merck KGaA, Darmstadt, Germany or it affiliates. All other trademarks are the property of their respective owners. Detailed information on trademarks is available via publicly accessible resources. The life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada.
*By submitting this form, you agree to receive more information on related products and services from the American Chemical Society (ACS Publications) via email, in accordance with the ACS Privacy Policy .

Copyright © 2024 American Chemical Society | 1155 Sixteenth Street NW | Washington, DC 20036 | View our Privacy Policy